非酒精性脂肪肝患者血清免疫球蛋白对肝纤维化的预测价值分析被引量：1

The Predictive Value of Serum Immunoglobulin in Patients With Non Alcoholic Fatty Liver Disease in Liver Fibrosis

下载PDF

导出

摘要目的探讨非酒精性脂肪肝（NAFLD）患者的血清免疫球蛋白（immunoglobulin Ig）与肝细胞脂肪变性程度及肝纤维化的相关性。方法回顾性分析2010年5月~2015年5月在我院住院诊治的102例NAFLD患者的临床资料,分析各指标在不同组间的差异及相关性;同时根据肝穿刺结果将肝纤维化患者分组,分析各指标在不同组间的差异及相关性。结果 NAFLD患者中38例诊断为肝纤维化,Logisitic多因素分析结果提示年龄、血小板、IgA、IgG、总Ig以及IgA/总Ig和患者肝纤维化级别具有正相关性（P〈0.05）。结论 NAFLD患者血清免疫球蛋白水平（IgA、IgG和总Ig）与肝纤维化程度呈正相关关系,对判断NAFLD患者疾病进展和预后有重要作用。 Objective To explore the relationship befween serum immunoglobulin （Ig） and the deterioration of hepatic fibrosis in non-alcoholic fatty liver disease patients. Methods A retrospective study was carried out in our hospital from May 2010-May 2015. Totally 102 patients with non-alcoholic fatty liver disease were enrolled in this study and all clinical data were collected and analyzed. Results 38 cases of NAFLD were diagnosed as hepatic fibrosis, Logisitic multiple factor analysis results that age, platelet, IgA, IgG, total Ig and IgA/total Ig were correlated with liver fibrosis stage in NAFLD （,~〈0.05）. Conclusion Serum immunoglobulin （IgA, lgG and total Ig） was positively correlated with deterioration of hepatocyte steatosis and fibrosis in NAFLD patients and it could be an independent risk factor in prognosis.

作者韩琳温巧生

机构地区上海交通大学医学院苏州九龙医院消化内科

出处《中国继续医学教育》 2015年第22期25-27,共3页 China Continuing Medical Education

关键词非酒精性脂肪肝免疫球蛋白肝纤维化 NAFLD, Serum immunoglobulin, Liver Fibrosis

分类号 R575 [医药卫生—消化系统]

引文网络
相关文献

参考文献8

1Ahmed MH, Abu EO, Byrne CD. Non-Alcoholic Fatty Liver Disease (NAFLD): new challenge for general practitioners and important burden for health authorities?[J]. Prim Care Diabetes, 2010, 4 (3): 129-137.
2McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management[J]. J Hepatol, 2015, 62 (5): 1148-1155.
3范建高.非酒精性脂肪性肝病诊疗指南(2010年修订版)[J].胃肠病学和肝病学杂志,2010,19(6):483-487. 被引量：409
4Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China[J]. J Hepatol, 2009, 50 ( 1 ) : 204-210.
5Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven- year prospective follow-up[J]. J Hepatol, 2012, 56 ( 5 ) : 1145- 1151.
6Zeshan Riaz MW. Advances in clinical hepatology and what the hepatologist expects from a liver biopsy result[J]. Diagnostic Histopathology, 2014, 20 ( 3 ) : 95-101.
7Cha vez-Tapia NC, Gonz a lez-Rodr i guez L, Jeong M, et al. Current evidence on the use of probiotics in liver diseases[J]. Journal ofFunctionalFoods, 2015, 17:137-151.
8Azza Karrar LZ, Ali Moosvi, Hunt Sharon L, et al. Prevalence and Significance of Serum Immunoglobulin M and G Concentration in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)[J]. Gastroenterology, 2013, 144 (5) : 909-911.